Differences in hippocampal volume (HV) that appear with advancing age represent cumulative effects of early life factors, life-course events, and disease. Hippocampal atrophy is a recognized biological marker of Alzheimer's disease (AD)^[@R1],[@R2]^; however, it is influenced by various vascular and metabolic factors^[@R3],[@R4]^. Because HV is a heritable^[@R5]^ widely measurable trait that exhibits meaningful detectable changes throughout the lifespan, it is a suitable endophenotype for aging-related physiological processes and presymptomatic diseases, improving power to detect genetic associations.

We explored genetic influences on HV by conducting a cross-sectional genome-wide association analysis in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium^[@R6]^ among 9,232 dementia-free persons from eight community-based studies whose mean age ranged from 56 to 84 years (weighted average, 67.1 years). Each study imputed to a common set of Phase II HapMap CEU SNPs using genotype data from Illumina or Affymetrix arrays; fit additive genetic models associating total hippocampal volume and genotype dosage with adjustment for age, sex, and familial relationships (if applicable, see [Supplementary Note](#SD2){ref-type="supplementary-material"}); and applied genomic control. Study-specific results were combined in an inverse-variance weighted meta-analysis.

We then conducted *in-silico* replication of our genome-wide significant associations and sought additional evidence for suggestive associations in a second-stage targeted meta-analysis of 2,318 subjects from two community-based studies: the Three City study and an independent sample from the third expansion of the Rotterdam study. Characteristics of the discovery and replication samples are shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

[Figure 1](#F1){ref-type="fig"} provides a Manhattan plot of -log~10~(p-values) from the discovery analysis, where p-values for 46 SNPs at four loci ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}) surpassed our replication threshold of p\<4.0×10^-7^ ---corresponding to one expected false positive. Of these, 18 SNPs at 2 loci surpassed a genome-wide significant threshold of p\<5.0×10^-8^: 12q14, which included *WIF1, LEMD3*, and *MSRB3*, and 12q24, which included *HRK* and *FBXW8*. We found evidence of replication (p\<0.01) for both associations. The remaining suggestive associations included SNPs on 2q24 within *DPP4* and on 9p33 within *ASTN2*, which had consistent directions of association in the replication phase, but did not attain genome-wide significance in a combined analysis. Estimates for each stage are shown in [Table 1](#T1){ref-type="table"}; discovery GWAS results for the each signal's surrounding region annotated with recombination rates and known genes are shown in [Figure 2](#F2){ref-type="fig"}; and study-specific findings appear in [Figure 3](#F3){ref-type="fig"}.

Below, we present association estimates for a meta-analysis combining the discovery and replication results for these four loci. To contextualize the magnitude of a SNP's association with HV, we divided the regression coefficient for the allele by the mean decrease in HV for each year of chronological age (-27.4 mm^3^ per year, estimated within the Framingham Heart Study).

The strongest association was for rs7294919, located on 12q24 between *HRK* and *FBXW8*, where each copy of the T allele (allele frequency \[AF\] = 0.91) was associated with lower HV (β=−107.8 mm^3^, p=2.9×10^-11^), equivalent to 3.9 years of aging.

*HRK* is expressed throughout the brain with highest levels in the amygdala, entorhinal cortex, and hippocampus^[@R7]^. It acts as a key regulator of apoptosis^[@R8]^, a complex pathway associated with aging, ischemia, and AD^[@R9]^ through its interaction with death-repressor proteins Bcl-2 and Bcl-X(L)^[@R10]^. In rat neuronal cell cultures, a homologous protein, DP5 (72% identity), is induced during Aβ-mediated cytotoxicity, withdrawal of nerve growth factor (NGF)^[@R11]^, and induced global ischemia^[@R12]^. While treatment strategies aimed at modifying the apoptotic pathway have yet to achieve success^[@R13]^, our findings suggest this area of therapeutics might remain promising.

*FBXW8* encodes the substrate-recognition component of an SCF (skip1, cullin1, F-box) E3 ubiquitin ligase found in the golgi apparatus of neurons. Different E3 ligase complexes target specific substrates for polyubiquitination leading to proteosome degradation^[@R14]^, suggesting a role in clearing abnormal and potentially toxic protein aggregates, particularly hyperphosphorylated tau^[@R15]^. Its role in presynaptic development^[@R16]^, synapse formation, neurotransmitter release, and promotion of dendrite growth in hippocampal neurons makes a genetic association with HV plausible^[@R17]^. Whether one or both *HRK* and *FBXW8* are involved in determining HV is unclear since rs7294919 is an eSNP associated with changes in both^[@R18]-[@R21]^.

At the 12q14 locus, the G allele for rs17178006, intronic within *MSRB3* (AF=0.10), was associated with decreased HV (β=−123.8 mm^3^, p=5.3×10^-11^) equivalent to 4.5 years of aging. *MSRB3* catalyzes the reduction of methionine R-sulfoxide residues in proteins and requires zinc or selenium as a cofactor. Thus, the association of lower selenium levels with elevated plasma homocysteine, which in turn has been associated with an increased risk of AD and hippocampal atrophy ^[@R22]-[@R24]^, may be mediated by suppression of MsrB in various organs including the brain^[@R25]^. Several SNPs in low linkage disequilibrium (*r^2^*=0.2) with rs17178006 were also associated with decreased HV, including rs6581612 (AF=0.27, β=−63.3 mm^3^, p=7.2×10^-11^) between *WIF1* and *LEMD3. WIF1* inhibits extracellular signaling Wnt proteins, which play a role in embryonic development---along with β-catenin---and hippocampal aging^[@R26]^. Changes in Wnt signaling mimic the effects of environmental enrichment increasing hippocampal synaptic densities^[@R27]^. *LEMD3* is a transforming growth factor-beta antagonist expressed in the hippocampus and upregulated protectively during ischemia and epileptogenesis^[@R28]-[@R30]^. Further, it interacts with progerin, the abnormal form of laminin A responsible for premature aging in progeria (Hutchinson-Gilford syndrome)^[@R31]^.

When testing for independent effects of these two SNPs in conditional models, both associations were attenuated, but only rs17178006 remained significant (p\<0.05, [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}), suggesting that the SNPs mark a single locus. Whereas *MSRB3* may be most influential, it remains possible that more than one gene in this region is associated with HV. For example, 8 eSNPs in the vicinity of this locus ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}) were associated with HV at a p-value ≤5.3×10^-4^ and have been reported to modify *LEMD3* expression.

In addition to the strong findings discussed above, SNPs at two additional loci showed suggestive evidence for association, but did not reach genome-wide significance in our combined meta-analysis. The first was rs6741949 in a *DPP4* intron on chromosome 2q24, where the G allele (AF=0.53) was associated with smaller hippocampal volume (β=−52.8 mm^3^, p=2.9×10^-7^). Many bioactive peptides whose levels are altered in AD and vascular brain injury are substrates for *DPP4*^[@R32]^, and *DPP4* reduces extracellular β-amyloid deposition in mouse models of AD^[@R33]^. Further, DPP4 is an intrinsic membrane glycoprotein and a widely expressed serine exopeptidase^[@R34]^. It is also an adipokine over expressed in visceral adipose tissue of obese persons and those with diabetes^[@R35]^, conditions associated with smaller HV^[@R3],[@R36]^. A novel class of antidiabetic medications (sitagliptin, and related incretin compounds) inhibits DPP4 to improve insulin sensitivity and glucose tolerance through increased levels of glucagon like proteins-1 and 2 (GLP-1, -2). Interestingly, endogenous incretin GLP-1 is also heavily expressed in some hippocampal neurons and has neuroprotective properties^[@R37]-[@R39]^.

The second suggestive association was for rs7852872, located in an *ASTN2* intron on chromosome 9 where the C allele (AF=0.63) was associated with lower hippocampal volume (β=−47.7 mm^3^, p= 1.0×10^-7^). *ASTN2* is a cell adhesion molecule expressed in neurons, including those in the dentate gyrus and hypothesized to function in glial-guided neuronal migration^[@R40],\ [@R41]^.

We sought additional replication of our significant and suggestive associations by testing the lead (or proxy) SNP from each locus in the Enhancing Neuro Imaging Genetics through Meta Analysis (ENIGMA) consortium. Briefly, this group (n=7,794, mean age 39.9 years) combined multiple studies including normal older individuals, a developmental sample, and cases symptomatic for cognitive or affective diseases. Among the ENIGMA sample, we observed a consistent direction of association for all cross-study comparisons. For the loci where the lead SNP was available in ENIGMA, replication was strongest at *HRK/FBXW8* (rs7294919, p=1.6×10^-7^) and nominal at *DPP4* (rs6741949, p=0.04). While the lead SNPs were not available at the other loci, one proxy SNP in weak (r^2^ = 0.3) linkage disequilibrium with rs17178006 (*MSRB3*) and another in strong LD with rs7852872 (*ASTN2*) both had p-values\< 0.05 in ENIGMA ([Table 2](#T2){ref-type="table"}).

Because the ENIGMA and CHARGE samples differed in two key aspects---ENIGMA's inclusion of younger adults (8 of 13 studies had no participants older than 65 years) and of some persons with cognitive impairment and dementia (13% of the sample)---we examined the top loci in subsamples of healthy persons (n=5,775, mean age 34.8 years) and of cognitively intact older persons (n=816, mean age 67.2 years). Association estimates, were generally similar to those of the full sample ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}).

Given the established relationship between hippocampal atrophy and AD, we investigated whether SNPs from published AD GWAS^[@R42]-[@R46]^ were associated with HV in our discovery meta-analysis ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}). We found nominal associations of risk alleles in four AD genes with smaller HV: *APOE* (p=0.005), *BIN1* (p=0.02), *MS4A4E* (p=0.001) and *TOMM40* (p=0.01). However, in aggregate, various known AD SNPs explained less than 1% of the observed variance in HV.

We also examined our five lead SNPs for associations with cognitive decline among 1,593 participants (mean age 78.6 years) in the Religious Orders Study and Rush Memory and Aging Project^[@R47]^ (described in [Supplementary Table 6](#SD2){ref-type="supplementary-material"}) and found that rs7852872 (*ASTN2* locus) was associated with an accelerated rate of global cognitive decline (p=0.009) and an accelerated rate of memory loss (p=0.01) ([Supplementary Figure 2 and Supplementary Table 7](#SD2){ref-type="supplementary-material"}). The magnitude of effect was comparable to that noted previously for a *CR1* SNP (rs6656401) in the same sample ^[@R28]^, providing evidence for the potential importance of this region.

The strengths of the current study include the large population-based sample. In the discovery sample, our power to detect genome-wide significant associations on the order of 0.2 standard deviations in HV (\~128 mm^3^, in the largest single sample: the AGES_Reykjavik study) was modest for rare variants (68% for 0.05 MAF) and strong for more common variants (\>99% for 0.10 MAF). Additional power estimates are shown in [Supplementary Figure 3](#SD2){ref-type="supplementary-material"}. The concordance of these associations in ENIGMA provides additional biological validation in a population that included younger persons, suggesting that these genes are developmentally important and may be related to maximal adult HV. ENIGMA also has a substantial proportion of persons with dementia, which indicates that these genes may remain important in regulating response to injury. The ability to explore the association of our lead SNPs with cognitive decline provided further context to our findings. Finally, we demonstrated modest associations between previously described Alzheimer's disease risk SNPs and smaller HV in our samples.

The study also has limitations. A single cross-sectional assessment was used in all studies and MRI and reading protocols varied across participating studies: some studies used manually-traced boundaries (the gold standard) whereas others used computerized algorithms. Although correlation between these two methods is good (Pearson's *r*=0.7)^[@R48]^, the heterogeneity of measurement techniques may have compromised our ability to detect small associations. Although our sample size was reasonably large, we may have missed associations with small effect sizes as well as rare variants not covered by commercial genotyping arrays.

Prior studies have suggested that cognitive, neuropathological, and MRI endophenotypes of AD might be early and more sensitive markers of genetic risk than clinical dementia. Hence, it could be argued that genes associated with AD risk should also be associated with HV, even in our dementia-free sample. Although four AD genes were associated with HV, several were not; so in this study HV was not a more sensitive measure than clinical AD. It is clear that genetic analysis of MRI endophenotypes within a healthy older community-based cohort study is not an ideal study design to identify all the genes associated with clinical AD. Our aim, however, was to identify genetic influences on hippocampal development and response to aging and not AD *per se*.

In summary, we detected four genetic loci associated with HV in a large, population-based, dementia-free sample. Two of these loci replicated in independent community-based samples as well as in ENIGMA, a mixed age sample that included some participants with cognitive impairment indicating that these loci may have broad implications for determining the integrity of the hippocampus across a range of ages and cognitive capacities. Findings from this study identified a series of relevant and potentially important genes associated with HV during development, with aging, and in the presence of Alzheimer's disease. Exploration of these genomic regions with dense genotyping, expression, and translational studies will be required to understand the role of these genes in determining HV.

Online Methods {#S1}
==============

Participating studies {#S2}
---------------------

Our analyses were performed among dementia-free participants within the setting of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.^[@R6]^ The ten discovery samples included the Aging Gene-Environment Susceptibility---Reykjavik Study (AGES), the Atherosclerosis Risk in Communities Study (ARIC), the Austrian Stroke Prevention Study (ASPS), the Erasmus Ruchphen Family study (ERF), the Framingham Heart Study (FHS), the Religious Order Study & Rush Memory and Aging Project (RUSH), three independent phases of the Rotterdam Study (RS I, RS II, RS III), and the Tasmanian Study of Cognition and Gait (TASCOG). The two second stage replication samples included the Three City Study (3C) and another independent sample of the third expansion of the Rotterdam Study (RS R). Details on the discovery samples and second stage studies can be found in the [Supplementary Note](#SD2){ref-type="supplementary-material"}. Each study has an Institutional Review Board that approved the consent procedures, examination components, data security processes, genotyping protocols and current study design. All participants gave written informed consent for study participation and for use of DNA for genetic research.

Hippocampal Volume Phenotypes {#S3}
-----------------------------

Each study evaluated the total hippocampal volume using 1T, 1.5T or 3T MRI and either operator-defined, manually traced boundaries drawn on serial coronal sections or automated methods according to previously described reading protocols. For these analyses, we used data from the baseline examination or the first examination in which an MRI measurement was obtained. Specific details for each study's MRI protocol are provided in the [Supplementary Note](#SD2){ref-type="supplementary-material"}.

Genotyping and imputation {#S4}
-------------------------

The studies in these analyses used commercial genotyping platforms available from Illumina or Affymetrix. Each study performed genotyping quality control checks and imputed the approximately 2.5 million polymorphic autosomal SNPs described in the HapMap CEU population for each participant using available imputation methods. Details of per-study genotyping, imputation, and quality control procedures are available in [Supplementary Note](#SD2){ref-type="supplementary-material"}.

Statistical analysis within studies {#S5}
-----------------------------------

Each study independently implemented a predefined GWAS analysis plan. For the continuous measure of hippocampal volume, we evaluated cross-sectional associations of hippocampal volume and genetic variation using linear regression models (or linear mixed effects models, in FHS and ERF to account for family relatedness). For each of the 2.5 million SNPs, each study fit additive genetic models, regressing trait on genotype dosage (0 to 2 copies of the variant allele). In our primary analyses, all studies adjusted for age and sex. Some studies made additional adjustments including study site, familial structure, or for whether the DNA had been whole genome amplified. Additional details of the statistical analyses are available in the [Supplementary Note](#SD2){ref-type="supplementary-material"}.

Discovery meta-analysis {#S6}
-----------------------

We conducted a meta-analysis of regression estimates and standard errors using an inverse-variance weighting approach as implemented in METAL^[@R49]^. After verification of strand alignment across studies, QC, filtering, and imputation within each study, we restricted our meta-analysis to autosomal SNPs that were reported in at least 2 studies and that had an average minor allele frequency of at least 1%. Prior to meta-analysis, we calculated a genomic inflation factor (λ~gc~) for each study to screen for cryptic population substructure or undiagnosed irregularities that might have inflated the test statistics. Inflation was low, with λ~gc~ below 1.05 in all studies. We applied "genomic control" to each study whose genomic inflation factor was greater than 1.00 by multiplying all of the standard errors by the square root of the study-specific λ~gc~. We express the association of each SNP and hippocampal volume as the regression slope (β), its standard error \[SE(β)\] and a corresponding p-value. Standardized gene and SNP annotations were created using a PERL program.^[@R50]^

For follow up, we decided *a priori* on a significance threshold of p \< 4×10^-7^, which corresponds to not more than one expected false positive finding over 2.5 million tests.

Replication meta-analysis {#S7}
-------------------------

Replication samples were drawn from external studies with available genetic data and measures of hippocampal volume. We provided each collaborating second stage study a list of signal SNPs that attained a p-value of p \< 4×10^-7^ and combined the results from these studies using a fixed-effects meta-analysis as described above.

Combined meta-analysis {#S8}
----------------------

Finally, we combined results from the discovery and second stage analyses using inverse variance weighting, as described above, and considered SNPs with a p-value \< 5×10^-8^ as genome-wide significant.

External Validation {#S9}
-------------------

We sought external replication for our significant and suggestive loci in the ENIGMA consortium, details can be found in the companion paper. The international ENIGMA consortium comprises a wide variety of studies that all have GWAS and hippocampal volume measures (<http://enigma.loni.ucla.edu>). The sample includes case-control studies of AD and depression, family-based and sib-pair samples as well as population based samples of varying ages and ethnicities (European, African and Hispanic). ENIGMA assesses brain volumes using Freesurfer/FSL-FIRST protocols in most samples but also uses other protocols in a few samples. Hence we chose to compare the results from ENIGMA and CHARGE in a qualitative manner as these two studies vary in the composition of the study sample participants as well as in the methods used to assess HV. We considered replication as a p-value of \< 0.05 and consistent direction of association.

Exploration of loci for eQTLs and functional variants {#S10}
-----------------------------------------------------

We examined the 4 loci identified as associated with HV for the presence of cis-eQTL associations using the website <http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl/eQTL>. We also searched for functional SNPs in LD with the 5 index SNPs. We identified over 70 SNPs with an r2 \>0.4 that were within 500kb of each index SNP using the SNAP proxy tool (<http://www.broadinstitute.org/mpg/snap/>) and annotated these SNPs using GeneCruiser (<http://genecruiser.broadinstitute.org/genecruiser3/>); none of these SNPs were exonic, non-synonymous coding SNPs.

Supplementary Material {#S11}
======================
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![Genome-wide Manhattan plot for hippocampal volume\
The plot shows the individual p-values (based on discovery meta-analysis) against their genomic position for hippocampal volume. Within each chromosome, shown on the *x*-axis, the results are plotted left to right from the p-terminal end. The dashed line indicates the threshold for follow-up, p\<4 ×10^-7^ and the solid line indicates the threshold for genome-wide significance, p\<5×10^-8^. The nearest genes are indicated above points that surpassed our significance threshold for follow-up.](nihms362237f1){#F1}

![Regional plots for hippocampal volume SNPs\
Plots are centered on the most significant SNP at a given locus along with the meta-analysis results for SNPs in a region surrounding it (typically ± 100kb). All SNPs are plotted with their discovery meta-analysis p-values against their genomic position, with the most significant SNP in the region indicated as a diamond and other SNPs shaded according to their pairwise correlation (*r^2^*) with the signal SNP. The light blue line represents the estimated recombination rates. Gene annotations are shown as dark green lines.](nihms362237f2){#F2}

![Forest plots for hippocampal volume SNP associations\
Plots show the study-specific association estimates (β) and 95% confidence intervals for the discovery and replication stage studies, presented as rectangles and bars. Arrowheads indicate confidence intervals that span beyond the x-axis. Study specific results are indicated by: AGES, Aging Gene-Environment Susceptibility---Reykjavik Study; ARIC, Atherosclerosis Risk in Communities Study, ASPS, Austrian Stroke Prevention Study; ERF, Erasmus Ruchphen Family study; FHS, Framingham Heart Study; RUSH, Religious Order Study & Rush Memory and Aging Project; RS I, RS II, RS III, RS R, independent phases of the Rotterdam Study; TASCOG, Tasmanian Study of Cognition and Gait; 3C, Three City Study. Estimates from the replication phase (3C, RS R) are indicated by open rectangles. The scale is mm^3^. The association estimate and confidence interval for the meta-analysis combining discovery and second stage results is presented as a diamond. Blank spaces indicate occasions in which a particular study was not able to provide results for a given SNP.](nihms362237f3){#F3}

###### 

Discovery, Replication, and Combined Meta-analysis

                                         Discovery Meta Analysis   Replication Meta Analysis   Discovery + Replication                                                                             
  ------- ------------ ----------- ----- ------------------------- --------------------------- ------------------------- ------------ ------- -------- ------ ------------ ------- -------- ------ -------------
  2q24    rs6741949    **DPP4**    G/C   0.53                      −61.4                       11.3                      5.2×10^-8^   6,673   −10.1    25.2   0.7          1,369   −52.8    10.3   2.9×10^-7^
  9q33    rs7852872    **ASTN2**   C/G   0.62                      −53.1                       10.0                      1.0×10^-7^   9,187   −25.0    20.4   0.2          2,318   −47.7    9.0    1.0×10^-7^
  12q14   rs17178006   **MSRB3**   G/T   0.10                      −121.0                      20.7                      5.5×10^-9^   5,249   −137.9   45.5   0.002        1,003   −123.8   18.9   5.3×10^-11^
          rs6581612    WIF1        C/A   0.27                      −60.5                       10.8                      2.2×10^-8^   9,183   −75.2    22.1   0.0007       2,318   −63.3    9.7    7.1×10^-11^
  12q24   rs7294919    HRK         T/C   0.91                      −97.7                       17.9                      4.8×10^-8^   8,089   −154.0   38.3   5.8×10^-5^   1,573   −107.8   16.2   2.9×10^-11^

A1/2 indicates coded (risk)/non-coded allele; B=association estimate, in mm^3^; SE=standard error, P=p-value, N_eff indicates effective sample size: Σ(imputation quality×N). **Bolded** gene names indicate that a SNP is within the gene.

###### 

Replication results in ENIGMA

  Locus   SNP           Gene          A1/2   AF     B        SE     P            N_Eff
  ------- ------------- ------------- ------ ------ -------- ------ ------------ -------
  2q24    rs6741949     **DPP4**      G/C    0.58   −28.2    14.0   0.04         7,794
                                                                                 
  9q33    rs7852872     **ASTN2**     C/G                                        
                                                                                 
          *rs7040792*   (r^2^=1.0)    T/C    0.64   −29.0    12.8   0.02         7,794
                                                                                 
  12q14   rs17178006    **MSRB3**     G/T                                        
          *rs1370938*   (r^2^=0.30)   A/C    0.24   −32.4    14.4   0.02         7,794
                                                                                 
          rs6581612     WIF1          C/A                                        
          *rs1498792*   (r^2^=0.96)   T/C    0.25   −25.4    14.6   0.08         7,794
                                                                                 
  12q24   rs7294919     HRK           T/C    0.90   −112.2   21.4   1.6×10^-7^   7,794

A1/2 indicates coded (risk)/non-coded allele; B=association estimate, in mm^3^; SE=standard error, P=p-value, N_eff indicates effective sample size. **Bolded** gene names indicate that a SNP is within the gene. Proxy SNPs are indicated in (italics); r^2^ indicates correlation in between these proxies and lead SNP in Phase II HapMap CEU sample.
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